Gilead’s twice-yearly shot to prevent HIV succeeds in late-stage trial
Publishing timestamp: 2024-06-20 12:22:16
Summary
Gilead's experimental twice-yearly medicine to prevent HIV was 100% effective in a late-stage trial, with none of the roughly 2000 women in the trial contracting HIV. The company needs to replicate the results in another Phase 3 trial before seeking FDA approval, but if successful, the medicine could reach the market as soon as late 2025. Shares of Gilead rose about 7% on the news.
Sentiment: POSITIVE
Tickers: GILD,
Keywords: gilead sciences inc, health care industry, business news, breaking news: business,
Source: https://www.cnbc.com/2024/06/20/gilead-prep-lenacapavir-succeeds-in-phase-3-trial.html